Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Vertex to Cut 15% of Workforce; Posts Loss

By Pharmaceutical Processing | October 29, 2013

Vertex Pharmaceuticals said that it is cutting 15 percent of its workforce as a competitor’s treatment for hepatitis C edges closer to approval. It also reported a loss for its fiscal third quarter, including lower-than-expected revenue.

DETAILS: Food and Drug Administration advisers last week voted in favor of a hepatitis C drug from Gilead Sciences that could help millions of Americans infected with the liver-destroying virus. The FDA is not required to follow the group’s advice, though it often does, which has increased expectations that the drug will reach the market.

Standard treatment for most of the last 20 years involved a grueling one-year regimen of pills and injections that causes flu-like symptoms and cured fewer than half of patients. In 2011, the FDA approved two new drugs, including Incivek from Vertex, that raised the cure rate when combined with the older treatments. Gilead’s once-a-day pill appears to push the cure rate even higher.

Given the pending threat to its existing hepatitis C business, Vertex said Tuesday that it will focus on opportunities in cystic fibrosis, an all-oral hepatitis C treatment and other research to position itself for future growth. It is cutting 370 jobs, primarily related to Incivek.

That move is expected to reduce 2014 operating expenses by $150 million to $200 million.

NUMBERS: Vertex posted a loss of $124.1 million, or 54 cents per share, for the quarter that ended Sept. 30. That is compared with a loss of $57.5 million, or 27 cents per share, last year.

The Cambridge, Mass., company recorded restructuring charges of $11 million in the third quarter tied to the job cuts. On an adjusted basis, the company posted a loss of 32 cents per share versus earnings of 13 cents per share last year.

Total revenue fell to $221.7 million from $336 million, as Incivek sales slid by two-thirds, to $85.6 million.

Analysts polled by FactSet were anticipating a loss of 33 cents per share with revenue of $275.1 million.

FUTURE: Vertex now expects total revenue of $1 billion to $1.5 billion for 2013, down from its forecast in July of revenue between $1.1 billion to $1.2 billion. Analysts had forecast $1.16 billion.

STOCK: Shares fell $2.05, or 2.6 percent, to $75.78 by midday.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE